Abstract
The integrin receptor αvβ3 has been shown to play a critical role in several distinct processes, such as angiogenesis, osteoclast-mediated bone resorption and tumor metastasis. Its expression is upregulated in newly synthesized blood vessels produced in response to a variety of tumors and purified angiogenic factors. Studies show that αvβ3 is a critical target downstream from perhaps all angiogenic factors. Proof-of-principle that αvβ3 antagonists such as monoclonal antibodies and small molecules block angiogenesis and tumor growth has been obtained in several animal models. Many endogenous inhibitors of angiogenesis such as angiostatin, endostatin and tumstatin seem to work through the αvβ3 receptor further emphasizing the critical role of this receptor in angiogenesis. In addition, the αvβ3 receptor has been clearly implicated in several pathological processes such as rheumatoid arthritis, osteoporosis, and metastasis of prostate cancer to bone. Thus αvβ3 may prove to be an important target for pharmacological intervention in more than one clinical setting.
Keywords: integrin family, integrin, tumor-induced angiogenesis, alpha v beta 3
Current Drug Targets
Title: Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis
Volume: 4 Issue: 2
Author(s): C. Chandra Kumar
Affiliation:
Keywords: integrin family, integrin, tumor-induced angiogenesis, alpha v beta 3
Abstract: The integrin receptor αvβ3 has been shown to play a critical role in several distinct processes, such as angiogenesis, osteoclast-mediated bone resorption and tumor metastasis. Its expression is upregulated in newly synthesized blood vessels produced in response to a variety of tumors and purified angiogenic factors. Studies show that αvβ3 is a critical target downstream from perhaps all angiogenic factors. Proof-of-principle that αvβ3 antagonists such as monoclonal antibodies and small molecules block angiogenesis and tumor growth has been obtained in several animal models. Many endogenous inhibitors of angiogenesis such as angiostatin, endostatin and tumstatin seem to work through the αvβ3 receptor further emphasizing the critical role of this receptor in angiogenesis. In addition, the αvβ3 receptor has been clearly implicated in several pathological processes such as rheumatoid arthritis, osteoporosis, and metastasis of prostate cancer to bone. Thus αvβ3 may prove to be an important target for pharmacological intervention in more than one clinical setting.
Export Options
About this article
Cite this article as:
Kumar Chandra C., Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis, Current Drug Targets 2003; 4 (2) . https://dx.doi.org/10.2174/1389450033346830
DOI https://dx.doi.org/10.2174/1389450033346830 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Animal Venoms have Potential to Treat Cancer
Current Topics in Medicinal Chemistry DNA Methyltransferase Inhibitors and their Therapeutic Potential
Current Topics in Medicinal Chemistry Steroid Receptor-Associated Immunophilins: Candidates for Diverse Drug-Targeting Approaches in Disease
Current Molecular Pharmacology Editorial [ Hot Topic: Therapeutic Potential of Peptide Motifs - Part III (Executive Editor: Jean-Claude Herve) ]
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology New Histopathological & Genetic Features to Improve Active Surveillance Selection for Low-Risk Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Hormonal Effects on Drug Metabolism Through the CYP System: Perspectives on Their Potential Significance in the Era of Pharmacogenomics
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Alpha9Alpha10 Nicotinic Acetylcholine Receptors as Target for the Treatment of Chronic Pain
Current Pharmaceutical Design Mechanisms of Cytotoxicity of Anticancer Titanocenes
Anti-Cancer Agents in Medicinal Chemistry Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65
Current Gene Therapy Recent Progress in the Synthesis and Biomedical Properties of Natural Biopolymer Composites
Current Medicinal Chemistry Machine Learning Quantitative Structure-Activity Relationships (QSAR) for Peptides Binding to the Human Amphiphysin-1 SH3 Domain
Current Proteomics Transforming Growth Factor Beta in Pancreatic Cancer
Current Pharmaceutical Biotechnology EMT Blockage Strategies: Targeting Akt Dependent Mechanisms for Breast Cancer Metastatic Behaviour Modulation
Current Gene Therapy Adipose Tissue: Something More than Just Adipocytes
Current Nutrition & Food Science In silico Methods for Designing Antagonists to Anti-apoptotic Members of Bcl-2 Family Proteins
Mini-Reviews in Medicinal Chemistry The Possibility of Preventive and Therapeutic Use of Green Tea Catechins in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Promotion of Insulin-Like Growth Factor-I Production by Sensory Neuron Stimulation; Molecular Mechanism(s) and Therapeutic Implications
Current Medicinal Chemistry Investigating the In Vivo Expression Patterns of miR-7 microRNA Family Members in the Adult Mouse Brain
MicroRNA Role of NF-κB in the Regulation of Cytochrome P450 Enzymes
Current Drug Metabolism